Human iPSC-based Cardiac Microphysiological System For Drug Screening Applications

Citations Over TimeTop 1% of 2015 papers

Abstract

Drug discovery and development are hampered by high failure rates attributed to the reliance on non-human animal models employed during safety and efficacy testing. A fundamental problem in this inefficient process is that non-human animal models cannot adequately represent human biology. Thus, there is an urgent need for high-content in vitro systems that can better predict drug-induced toxicity. Systems that predict cardiotoxicity are of uppermost significance, as approximately one third of safety-based pharmaceutical withdrawals are due to cardiotoxicty. Here, we present a cardiac microphysiological system (MPS) with the attributes required for an ideal in vitro system to predict cardiotoxicity: i) cells with a human genetic background; ii) physiologically relevant tissue structure (e.g. aligned cells); iii) computationally predictable perfusion mimicking human vasculature; and, iv) multiple modes of analysis (e.g. biological, electrophysiological, and physiological). Our MPS is able to keep human induced pluripotent stem cell derived cardiac tissue viable and functional over multiple weeks. Pharmacological studies using the cardiac MPS show half maximal inhibitory/effective concentration values (IC₅₀/EC₅₀) that are more consistent with the data on tissue scale references compared to cellular scale studies. We anticipate the widespread adoption of MPSs for drug screening and disease modeling.

Related Papers

• The cardiotoxicity of anticancer agents.(1982)
• → Biomarkers, metabonomics, and drug development: Can inborn errors of metabolism help in understanding drug toxicity?(2007)46 cited
• → Drug Induced Cardiotoxicity: Mechanism, Prevention and Management(2018)28 cited
• → Microparticles and cardiotoxicity secondary to doxorubicin-based chemotherapy in breast cancer patients(2023)2 cited
• → Abstract 5063: Predicting target driven toxicity for small molecule inhibitors to aid in drug development(2022)